Skip to content

Fibroids in Women of Reproductive Age and Women Pregnancy

Uterine Fibroids Are a Very Common Finding in Women of Reproductive Age. Ready Safety Study Dydrogesterone + Multivitamin Nature in Women of Reproductive Age and Women Pregnancy

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02620345
Acronym
Fibroids
Enrollment
22
Registered
2015-12-03
Start date
2010-01-31
Completion date
2015-11-30
Last updated
2015-12-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fibroids

Keywords

Fibroids

Brief summary

Dydrogesterone Multivitamin Nature treatment of fibroids in women of reproductive age and women pregnancy to lost the size fibroids.

Detailed description

Uterine fibroids are a very common finding in women of reproductive age. But may fibroids grow in the first trimester pregnancy. Clinically has shown that: Uterine fibroids are associated with an Heavy or prolonged menstrual periods. Abnormal bleeding between menstrual periods. Uterine fibroids are associated with an increased rate of spontaneous miscarriage, preterm labor, placenta abruption, malpresentation, labor dystocia, cesarean delivery, and postpartum hemorrhage, pain is the most common complication of fibroids during pregnancy. Can usually be controlled by conservative treatment on Dydrogesterone Multivitamin nature.

Interventions

DRUGDydrogesterone M ( case 1 )

Dydrogesterone Multivitamin nature * Fibroids / Women Pregnancy ( discovered fibroids during pregnancy ) Dydrogesterone Multivitamin nature. * 1tablet/24 hours/day (to 4 weeks after postpartum)

DRUGDydrogesterone M ( case 2 )

Dydrogesterone Multivitamin nature * Fibroids/ Women of Reproductive age ( discovered fibroids ) * 1tablet/24 hours/day ( from discovered fibroids through 6 months)

Sponsors

Trieu, Nguyen Thi, M.D.
Lead SponsorINDIV

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 35 Years
Healthy volunteers
Yes

Inclusion criteria

* Procedure to treatment of fibroids in pregnancy and in women desiring future fertility.

Exclusion criteria

* Whether or not you are having symptoms from the fibroids * If you might want to become pregnant in the future * The size of the fibroids * The location of the fibroids * Your age and you might be

Design outcomes

Primary

MeasureTime frameDescription
Measure of fibroid size in millimetersfrom 4 weeks to 20 weeks* Patients fulfilling inclusion and exclusion criteria. * Measure to have Fibroids size \> 50mm x 60mm. * Will be divided into two groups Group (A): Women Pregnancy. * Measure of fibroid size in millimeters \< 50mm x 60mm. Group (B): Women Reproductive age. * Measure of fibroid size in millimeters \< 50mm x 60mm.

Secondary

MeasureTime frameDescription
Measure of fibroid size in millimetersfrom 20 weeks to 48 weeksGroup (A):Women Pregnancy. \- Measure of fibroid size in millimeters to loss the fibroids. Group (B): Women Reproductive age \- Measure of fibroid size in millimeters to loss the fibroids.

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026